Lipid-protein interactions regulating the canonical and the non-canonical NLRP3 inflammasome

Mariathasan, 2006, Cryopyrin activates the inflammasome in response to toxins and ATP, Nature, 440, 228, 10.1038/nature04515 Mayor, 2006, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature, 440, 237, 10.1038/nature04516 Duewell, 2010, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 464, 1357, 10.1038/nature08938 Hornung, 2008, Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization, Nat. Immunol., 9, 847, 10.1038/ni.1631 Heneka, 2013, NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice, Nature, 493, 674, 10.1038/nature11729 Patel, 2017, Inflammasome priming in sterile inflammatory disease, Trends Mol. Med., 23, 165, 10.1016/j.molmed.2016.12.007 Baker, 2017, Posttranslational modification as a critical determinant of cytoplasmic innate immune recognition, Physiol. Rev., 97, 1165, 10.1152/physrev.00026.2016 Andreeva, 2021, NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation, Cell, 184, 6299, 10.1016/j.cell.2021.11.011 Hochheiser, 2022, Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3, Nature, 604, 184, 10.1038/s41586-022-04467-w Ohto, 2007, Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa, Science, 316, 1632, 10.1126/science.1139111 Martín-Sánchez, 2017, Lytic cell death induced by melittin bypasses pyroptosis but induces NLRP3 inflammasome activation and IL-1β release, Cell Death Dis., 8, e2984, 10.1038/cddis.2017.390 Tapia-Abellán, 2021, Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation, Sci. Adv., 7, 10.1126/sciadv.abf4468 Di, 2018, The TWIK2 potassium Efflux Channel in macrophages mediates NLRP3 Inflammasome-induced inflammation, Immunity, 49, 56, 10.1016/j.immuni.2018.04.032 Pelegrin, 2021, P2X7 receptor and the NLRP3 inflammasome: partners in crime, Biochem. Pharmacol., 187, 10.1016/j.bcp.2020.114385 Muñoz-Planillo, 2013, K+ efflux is the common trigger of NLRP3 Inflammasome activation by bacterial toxins and particulate matter, Immunity, 38, 1142, 10.1016/j.immuni.2013.05.016 Groß, 2016, K + efflux-independent NLRP3 Inflammasome activation by small molecules targeting mitochondria, Immunity, 45, 761, 10.1016/j.immuni.2016.08.010 Chen, 2018, PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation, Nature, 564, 71, 10.1038/s41586-018-0761-3 Magupalli, 1979, HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation, Science, 2020, 369 He, 2016, NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux, Nature, 530, 354, 10.1038/nature16959 Sharif, 2019, Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome, Nature, 570, 338, 10.1038/s41586-019-1295-z Boucher, 2018, Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity, J. Exp. Med., 215, 827, 10.1084/jem.20172222 Lu, 2014, Unified polymerization mechanism for the assembly of ASC-dependent Inflammasomes, Cell, 156, 1193, 10.1016/j.cell.2014.02.008 Magupalli, 1979, HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation, Science, 2020 Schmidt, 2016, A single domain antibody fragment that recognizes the adaptor ASC defines the role of ASC domains in inflammasome assembly, J. Exp. Med., 213, 771, 10.1084/jem.20151790 Xia, 2021, Gasdermin D pore structure reveals preferential release of mature interleukin-1, Nature, 593, 607, 10.1038/s41586-021-03478-3 Evavold, 2018, The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages, Immunity, 48, 35, 10.1016/j.immuni.2017.11.013 Rühl, 2018, ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation, Science, 362, 956, 10.1126/science.aar7607 Broz, 2020, The gasdermins, a protein family executing cell death and inflammation, Nat. Rev. Immunol., 20, 143, 10.1038/s41577-019-0228-2 Wang, 2020, Structural mechanism for GSDMD targeting by autoprocessed caspases in Pyroptosis, Cell, 180, 941, 10.1016/j.cell.2020.02.002 Aglietti, 2016, GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes, Proc. Natl. Acad. Sci. U. S. A., 113, 7858, 10.1073/pnas.1607769113 Kayagaki, 2021, NINJ1 mediates plasma membrane rupture during lytic cell death, Nature, 591, 131, 10.1038/s41586-021-03218-7 Torre-Minguela, 2021, Gasdermins mediate cellular release of mitochondrial DNA during pyroptosis and apoptosis, FASEB J., 35, 1, 10.1096/fj.202100085R Baroja-Mazo, 2014, The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response, Nat. Immunol., 15, 738, 10.1038/ni.2919 Franklin, 2014, The adaptor ASC has extracellular and “prionoid” activities that propagate inflammation, Nat. Immunol., 15, 727, 10.1038/ni.2913 Zanoni, 2016, An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells, Science (New York, N.Y.), 352, 1232, 10.1126/science.aaf3036 Kayagaki, 1979, Noncanonical inflammasome activation by intracellular LPS independent of TLR4, Science, 2013, 1246 Schmid-Burgk, 2015, Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells, Eur. J. Immunol., 45, 2911, 10.1002/eji.201545523 Baker, 2015, NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5, Eur. J. Immunol., 45, 2918, 10.1002/eji.201545655 Kayagaki, 2011, Non-canonical inflammasome activation targets caspase-11, Nature, 479, 117, 10.1038/nature10558 Kayagaki, 2015, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling, Nature, 526, 666, 10.1038/nature15541 Deets, 2021, Inflammasomes and adaptive immune responses, Nat. Immunol., 22, 412, 10.1038/s41590-021-00869-6 Karki, 2019, Diverging inflammasome signals in tumorigenesis and potential targeting, Nat. Rev. Cancer, 19, 197, 10.1038/s41568-019-0123-y Missiroli, 2021, Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer, Cancers, Vol 13, 2297, 10.3390/cancers13102297 Mangan, 2018, Targeting the NLRP3 inflammasome in inflammatory diseases, Nat. Rev. Drug Discov., 17, 588, 10.1038/nrd.2018.97 Swanson, 2019, The NLRP3 inflammasome: molecular activation and regulation to therapeutics, Nat. Rev. Immunol., 19, 477, 10.1038/s41577-019-0165-0 de Torre-Minguela, 2017, Mesa del Castillo P, Pelegrín P. the NLRP3 and pyrin Inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Frontiers in, Immunology, 8, 43 Tapia-Abellán, 2019, MCC950 closes the active conformation of NLRP3 to an inactive state, Nat. Chem. Biol., 15, 560, 10.1038/s41589-019-0278-6 Mensa-Vilaro, 2016, Late onset cryopyrin-associated periodic syndrome due to myeloid-restricted somatic NLRP3 mosaicism, Arthritis Rheum., 68, 3035, 10.1002/art.39770 Bertoni, 2020, A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: therapeutic efficacy of proton pump inhibitors, J. Allergy Clin. Immunol., 145, 368, 10.1016/j.jaci.2019.05.034 Brydges, 2009, Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity, Immunity, 30, 875, 10.1016/j.immuni.2009.05.005 Meng, 2009, A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses, Immunity, 30, 860, 10.1016/j.immuni.2009.04.012 Klück, 2020, Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial, Lancet Rheumatol., 2, e270, 10.1016/S2665-9913(20)30065-5 Wohlford, 2020, Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the Oral NLRP3 inhibitor Dapansutrile in subjects with NYHA II-III systolic heart failure, J. Cardiovasc. Pharmacol., 77, 49, 10.1097/FJC.0000000000000931 Alarcón-Vila, 2019, Purinergic receptors and the inflammatory response mediated by lipids, Curr. Opin. Pharmacol., 47, 90, 10.1016/j.coph.2019.02.004 Wymann, 2008, Lipid signalling in disease, Nat. Rev. Mol. Cell Biol., 9, 162, 10.1038/nrm2335 Elliott, 2018, Cutting edge: mitochondrial assembly of the NLRP3 Inflammasome complex is initiated at priming, J. Immunol., 200, 3047, 10.4049/jimmunol.1701723 Ohto, 2022, Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation, Proc. Natl. Acad. Sci. U. S. A., 119, 10.1073/pnas.2121353119 de la Roche, 2018, Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation, J. Cell Biol., 217, 3560, 10.1083/jcb.201709057 Ruysschaert, 2015, Role of lipid microdomains in TLR-mediated signalling, Biochim. Biophys. Acta Biomembr., 1848, 1860, 10.1016/j.bbamem.2015.03.014 Angosto-Bazarra, 2021, Techniques to study Inflammasome activation and inhibition by small molecules, Molecules, 26, 1704, 10.3390/molecules26061704 Platt, 2016, Immune dysfunction in Niemann-pick disease type C, J. Neurochem., 136, 74, 10.1111/jnc.13138 Iyer, 2013, Mitochondrial cardiolipin is required for NLRP3 inflammasome activation, Immunity, 39, 311, 10.1016/j.immuni.2013.08.001 Pizzuto, 2020, Cardiolipin in immune signaling and cell death, Trends Cell Biol., 30, 892, 10.1016/j.tcb.2020.09.004 Tapia-Abellán, 2021, Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation, Sci. Adv., 7, 10.1126/sciadv.abf4468 Berliner, 2009, The role of oxidized phospholipids in atherosclerosis, J. Lipid Res., 50, S207, 10.1194/jlr.R800074-JLR200 Aguilar-Ballester, 2020, Impact of cholesterol metabolism in immune cell function and atherosclerosis, Nutrients, 12, 1, 10.3390/nu12072021 Corrêa, 2020, Lysophosphatidylcholine induces NLRP3 inflammasome-mediated foam cell formation and pyroptosis in human monocytes and endothelial cells, Front. Immunol., 10, 2927, 10.3389/fimmu.2019.02927 Grebe, 2013, Cholesterol crystals and inflammation, Curr. Rheumatol. Rep., 15, 313, 10.1007/s11926-012-0313-z Duewell, 2010, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 464, 1357, 10.1038/nature08938 Zanoni, 2016, An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells, Science, 352, 1232, 10.1126/science.aaf3036 Chu, 2018, The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages, Nat. Commun., 9, 996, 10.1038/s41467-018-03409-3 Chang, 2004, Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory, J. Exp. Med., 200, 1359, 10.1084/jem.20031763 Podrez, 2002, Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36, J. Biol. Chem., 277, 38503, 10.1074/jbc.M203318200 Watson, 1999, Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein, J. Biol. Chem., 274, 24787, 10.1074/jbc.274.35.24787 Gaidt, 2016, Human monocytes engage an alternative Inflammasome pathway, Immunity, 44, 833, 10.1016/j.immuni.2016.01.012 Yeon, 2017, Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages, J. Leukoc. Biol., 101, 205, 10.1189/jlb.3VMA1215-579RR Oskolkova, 2010, Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation, J. Immunol., 185, 7706, 10.4049/jimmunol.0903594 Liu-Wu, 1998, Lysophosphatidylcholine induces the production of IL-1β by human monocytes, Atherosclerosis, 137, 351, 10.1016/S0021-9150(97)00295-5 Stock, 2006, Lysophosphatidylcholine stimulates IL-1β release from microglia via a P2X 7 receptor-independent mechanism, J. Immunol., 177, 8560, 10.4049/jimmunol.177.12.8560 Rajamäki, 2010, Cholesterol crystals activate the NLRP3 Inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation, PLoS One, 5, 10.1371/journal.pone.0011765 Cao, 2020, Multiple roles of 25-hydroxycholesterol in lipid metabolism, antivirus process, inflammatory response, and cell survival, Oxidative Med. Cell. Longev., 2020, 10.1155/2020/8893305 Jang, 2016, 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome, Nat. Commun., 7, 10.1038/ncomms13129 Reboldi, 1979, 25-hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon, Science, 2014, 679 Alegría Ezquerra, 2008, Obesity, metabolic syndrome and diabetes: cardiovascular implications and therapy, Rev. Esp. Cardiol., 61, 752, 10.1157/13123996 Vandanmagsar, 2011, The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance, Nat. Med., 17, 179, 10.1038/nm.2279 Luheshi, 2012, Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages, Eur. J. Immunol., 42, 716, 10.1002/eji.201142079 Yan, 2013, Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 Inflammasome activation, Immunity, 38, 1154, 10.1016/j.immuni.2013.05.015 L’homme, 2013, Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages, J. Lipid Res., 54, 2998, 10.1194/jlr.M037861 Gianfrancesco, 2019, Saturated fatty acids induce NLRP3 activation in human macrophages through K + efflux resulting from phospholipid saturation and Na, K-ATPase disruption, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1864, 1017, 10.1016/j.bbalip.2019.04.001 Karasawa, 2018, Saturated fatty acids undergo intracellular crystallization and activate the NLRP3 Inflammasome in macrophages, Arterioscler. Thromb. Vasc. Biol., 38, 744, 10.1161/ATVBAHA.117.310581 Wen, 2011, Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat. Immunol., 12, 408, 10.1038/ni.2022 de Carvalho, 2019, Leishmania lipophosphoglycan triggers Caspase-11 and the non-canonical activation of the NLRP3 inflammasome, Cell Rep., 26, 429, 10.1016/j.celrep.2018.12.047 Aachoui, 1979, Caspase-11 protects against bacteria that escape the vacuole, Science, 2013, 975 Santos, 2018, LPS targets host guanylate-binding proteins to the bacterial outer membrane for non-canonical inflammasome activation, EMBO J., 37, 10.15252/embj.201798089 Hagar, 1979, Cytoplasmic LPS activates Caspase-11: implications in TLR4-independent endotoxic shock, Science, 2013, 1250 Deng, 2018, The endotoxin delivery protein HMGB1 mediates Caspase-11-dependent lethality in Sepsis, Immunity, 0, 1 Santos, 2018, Sensing of invading pathogens by GBPs: at the crossroads between cell-autonomous and innate immunity, J. Leukoc. Biol., 104, 729, 10.1002/JLB.4MR0118-038R Meunier, 2014, Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases, Nature, 509, 366, 10.1038/nature13157 Lagrange, 2018, Human caspase-4 detects tetra-acylated LPS and cytosolic Francisella and functions differently from murine caspase-11, Nat. Commun., 9, 10.1038/s41467-017-02682-y Gay, 2007, Structure and function of {Toll} receptors and their ligands, Annu. Rev. Biochem., 76, 141, 10.1146/annurev.biochem.76.060305.151318 Santos, 2020, Human GBP1 binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria, Nat. Commun., 11, 10.1038/s41467-020-16889-z Wandel, 2020, Guanylate-binding proteins convert cytosolic bacteria into caspase-4 signaling platforms, Nat. Immunol., 21, 880, 10.1038/s41590-020-0697-2 Brubaker, 2020, A rapid Caspase-11 response induced by IFNγ priming is independent of guanylate binding proteins, IScience, 23, 10.1016/j.isci.2020.101612 Pizzuto, 2022, Ornithine lipid activates both TLR4 and the non-canonical NLRP3 Inflammasome, BioRxiv Kim, 2018, Bacterial ornithine lipid, a surrogate membrane lipid under phosphate-limiting conditions, plays important roles in bacterial persistence and interaction with host, Environ. Microbiol., 20, 3992, 10.1111/1462-2920.14430 Barbosa, 2018, Accumulation of ornithine lipids in Vibrio cholerae under phosphate deprivation is dependent on VC0489 (OlsF) and PhoBR system, Microbiol. (U. K.), 164, 395, 10.1099/mic.0.000607 Vences-Guzmán, 2012, Ornithine lipids and their structural modifications: from A to E and beyond, FEMS Microbiol. Lett., 335, 1, 10.1111/j.1574-6968.2012.02623.x Córdoba-Castro, 2021, Ornithine lipids in Burkholderia spp. Pathogenicity, Front. Mol. Biosci., 7, 457, 10.3389/fmolb.2020.610932 Okemoto, 2008, The preparation of a lipidic endotoxin affects its biological activities, Biol. Pharm. Bull., 31, 1952, 10.1248/bpb.31.1952 Kawai, 1989, Macrophage activation by an ornithine-containing lipid or a serine-containing lipid, Infect. Immun., 57, 2086, 10.1128/iai.57.7.2086-2091.1989 Kawai, 1991, Protection of mice from lethal endotoxemia by use of an ornithine-containing lipid or a serine-containing lipid, Infect. Immun., 59, 2560, 10.1128/iai.59.8.2560-2566.1991 Lonez, 2008, Cationic liposomal lipids: from gene carriers to cell signaling, Prog. Lipid Res., 47, 340, 10.1016/j.plipres.2008.03.002 Witzigmann, 2020, Lipid nanoparticle technology for therapeutic gene regulation in the liver, Adv. Drug Deliv. Rev., 159, 344, 10.1016/j.addr.2020.06.026 Felgner, 1987, Lipofection: a highly efficient, lipid-mediated {DNA}-transfection procedure, Proc. Natl. Acad. Sci. U. S. A., 84, 7413, 10.1073/pnas.84.21.7413 Akinc, 2019, The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs, Nat. Nanotechnol., 14, 1084, 10.1038/s41565-019-0591-y S S, J F, H A, KI K, K H, N I, 1997, Human immunodeficiency virus type-1-specific immune responses induced by DNA vaccination are greatly enhanced by mannan-coated diC14-amidine, Eur. J. Immunol., 27, 3121, 10.1002/eji.1830271207 Jacquet, 2005, Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite, Mol. Ther., 11, 960, 10.1016/j.ymthe.2004.12.024 Wilmar, 2012, The cationic lipid, diC14 amidine, extends the adjuvant properties of aluminum salts through a TLR-4- and caspase-1-independent mechanism, Vaccine, 30, 414, 10.1016/j.vaccine.2011.10.071 Tahtinen, 2022, IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines, Nat. Immunol., 23, 532, 10.1038/s41590-022-01160-y Pizzuto, 2016, Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers, J. Control. Release, 247, 182, 10.1016/j.jconrel.2016.12.029 Lonez, 2015, Critical residues involved in toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface, Cell. Mol. Life Sci., 72, 3971, 10.1007/s00018-015-1915-1 Lonez, 2014, Cationic lipid nanocarriers activate toll-like receptor 2 and NLRP3 inflammasome pathways, Nanomedicine, 10, 775, 10.1016/j.nano.2013.12.003 Lonez, 2009, Cationic lipids activate cellular cascades. Which receptors are involved?, Biochim. Biophys. Acta Gen. Subj., 1790, 425, 10.1016/j.bbagen.2009.02.015 Pizzuto, 2018, Cationic lipids as one-component vaccine adjuvants: a promising alternative to alum, J. Control. Release, 287, 67, 10.1016/j.jconrel.2018.08.020 Qin, 1997, Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression, Hum. Gene Ther., 8, 2019, 10.1089/hum.1997.8.17-2019 He, 2019, Membrane fusogenic lysine type lipid assemblies possess enhanced NLRP3 inflammasome activation potency, Biochem. Biophys. Rep., 18 Li, 2018, Lysine-containing cationic liposomes activate the NLRP3 inflammasome: effect of a spacer between the head group and the hydrophobic moieties of the lipids, Nanomedicine, 14, 279, 10.1016/j.nano.2017.10.011 Samaridou, 2020, Lipid nanoparticles for nucleic acid delivery: current perspectives, Adv. Drug Deliv. Rev., 154–155, 37, 10.1016/j.addr.2020.06.002 Dinarello, 2018, Overview of the IL-1 family in innate inflammation and acquired immunity, Immunol. Rev., 281, 8, 10.1111/imr.12621 Lee, 2003, Lipid-protein interactions in biological membranes: a structural perspective, Biochim. Biophys. Acta, 1612, 1, 10.1016/S0005-2736(03)00056-7